2019 - Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903
SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) article in Bioorganic and Medicinal Chemistry Letters (2019)
Sharma, S.H., Pablo J.L., Montesinos, M.S., Greka, A., Hopkins, C.R.
Bioorganic and Medicinal Chemistry Letters (2019) 29(2): 155-159
The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.